According to ORTHOWORLD, joint replacement “is orthopedics’ largest segment, accounting for 37% of the $65 billion overall market. Joint replacement’s mid-single digit growth rate has remained steady and could represent the “new normal” for the segment.”
As a stock market analyst, numbers like that get my attention. I am always on the lookout for a niche of the economy that Wall Street has overlooked.
Especially when it comes to healthcare, which from Wall Street’s perspective consists primarily of pharmaceutical companies and not much else. Last year, pharmaceutical sales exceeded $500 billion in the United States.
The same demographic trends driving pharmaceutical sales apply to joint replacement…
This post originally appeared at Investing Daily.